Factors Related to Relapse in Patients with Substance-related Disorders under Methadone Maintenance Therapy: Decision Tree Analysis.
Decision Trees
Iran
Methadone
Substance-Related Disorders
Journal
Oman medical journal
ISSN: 1999-768X
Titre abrégé: Oman Med J
Pays: Oman
ID NLM: 101526350
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
20
03
2019
accepted:
06
05
2019
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
30
1
2020
Statut:
epublish
Résumé
We sought to determine the main factors related to relapse in patients with substance-related disorders (SRDs) who received methadone maintenance therapy (MMT) using decision tree (DT) analysis. We conducted a cross-sectional study of 4175 patients referred to the 45 MMT centers in Kermanshah province, west of Iran. We included all patients who were under MMT for at least one year. All information was collected through an interview by a psychologist. Descriptive statistics and univariate and multiple regression models were used in statistical analysis. The Gini index was calculated to determine the cut-off point of nodes. We used the Classification and Regression Trees algorithm to create the DT. The relapse rate was 76.6% for all participants, with no significant gender differences. The DT resulted in a five-level model of significant factors affecting substance abuse relapse. These included lower cost for buying substances, lower age at first substance use, history of quitting substances without medication, frequency of substances utilization per month, and frequency of methadone therapy. Knowing the main factors associated with substance abuse relapse could be important for health care providers to make better decisions for improving the treatment outcomes of SRDs.
Identifiants
pubmed: 31993227
doi: 10.5001/omj.2020.07
pii: OMJ-35-01-1900059
pmc: PMC6976887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e89Informations de copyright
The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.
Références
Psychiatr Serv. 2005 Oct;56(10):1282-7
pubmed: 16215196
Psychol Rep. 2000 Jun;86(3 Pt 1):763-70
pubmed: 10876324
Oman Med J. 2015 May;30(3):173-80
pubmed: 26171123
Arch Iran Med. 2015 Aug;18(8):480-5
pubmed: 26265515
J Subst Abuse Treat. 2017 Jun;77:107-114
pubmed: 28476262
Pain. 2013 Nov;154(11):2287-96
pubmed: 23792283
Arch Gen Psychiatry. 2002 Apr;59(4):375-80
pubmed: 11926938
Int J High Risk Behav Addict. 2015 Sep 01;4(3):e23402
pubmed: 26495256
Glob J Health Sci. 2014 Feb 28;6(3):138-44
pubmed: 24762356
Oman Med J. 2016 Sep;31(5):327-31
pubmed: 27602185
Lancet. 2013 Nov 9;382(9904):1564-74
pubmed: 23993281
Int J High Risk Behav Addict. 2014 Jun 15;3(2):e16381
pubmed: 25032159
Lancet. 2014 Jan 18;383(9913):245-54
pubmed: 24449944
J Community Health. 2017 Dec;42(6):1090-1095
pubmed: 28444484
Oman Med J. 2018 Nov;33(6):512-519
pubmed: 30410694
J Subst Abuse Treat. 2014 Apr;46(4):482-90
pubmed: 24462221
Psychol Addict Behav. 2008 Sep;22(3):372-9
pubmed: 18778130
Addict Behav. 2013 Dec;38(12):2847-50
pubmed: 24018229
Environ Health Prev Med. 2016 Nov;21(6):480-486
pubmed: 27699691
Psychopharmacol Bull. 1966 Jul;3(3):1-12
pubmed: 5915847
Oman Med J. 2018 Jul;33(4):291-298
pubmed: 30038728
J Abnorm Psychol. 2016 Oct;125(7):946-959
pubmed: 27537477
Addict Health. 2009 Summer;1(1):44-51
pubmed: 24494082
Addict Behav. 1989;14(3):291-300
pubmed: 2787585
Arch Pediatr Adolesc Med. 2006 Jul;160(7):739-46
pubmed: 16818840
Addict Behav. 2017 May;68:45-51
pubmed: 28088743
Asian J Psychiatr. 2015 Aug;16:78-83
pubmed: 26168763
Ir Med J. 2010 Jun;103(6):176-9
pubmed: 20669601